Tech Transfer Central
Industry-Sponsored Research Management

Global Personalized Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts

Published by CurrentPartnering
Format: PDF, Email Delivery, CD-Rom
Publication Date: June 2015
1,546(including appendices) pages

Share:
Twitter Facebook Linkedin Pinterest Email
Price: Starting at $3,495
order button view cart

Global Personalized Medicine PartneringThe report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1000 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. The chapter also includes deal trends by big pharma and most active of all biopharma.

Chapter 3 covers the average financial deal terms for deals signed in the personalized medicine field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.

Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in personalized medicine partnering and dealmaking since 2010.

Chapter 4 provides a review of the leading biomarker deals since 2010 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a review of the leading companion diagnostics deals since 2010 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 6 provides a review of the leading pharmacogenomics deals since 2010 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 7 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 10 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 11 provides a comprehensive and detailed review of personalized medicine partnering deals signed and announced since January 2010. The chapter is organized by specific personalized medicine, biomarkers, companion diagnostics and pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 12 brings the report to a conclusion by looking ahead to the future of personalized medicine partnering. Newly introduced to provide readers with potential prospects and partnering insights this chapter selects emerging companies to watch in 2015 and details their recent deal making and financial activities. These companies could be potential targets for those who want to invest or partner in the coming months.

In addition, a comprehensive appendix is provided organized by personalized medicine partnering company A-Z , deal type, and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Report scope

Personalized Medicine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to personalized medicine trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine Partnering Terms and Agreements includes:

  • Trends in personalized medicine dealmaking in the biopharma industry since 2010
  • Analysis of personalized medicine deal structure
  • Access to headline, upfront, milestone and royalty data and contract documents
  • Case studies of real-life personalized medicine deals
  • Access to over 1000 personalized medicine deal announcements
  • The leading personalized medicine deals by value since 2010
  • Most active personalized medicine dealmakers since 2010
  • The leading personalized medicine partnering resources In Personalized Medicine Partnering Terms and Agreements, the available contracts are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1000 personalized medicine deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise personalized medicine rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture? o How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
order button
view cart


Click here for a printable order form